Dyne Therapeutics Inc Ordinary Shares DYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $17.04
- Day Range
- $16.56–17.29
- 52-Week Range
- $8.06–25.00
- Bid/Ask
- $6.73 / $21.00
- Shares Outstanding
- 165.31M
- Market Cap
- $2.78B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 258
- Website
- https://www.dyne-tx.com
Valuation
|
Metric
|
DYN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DYN
Financial Strength
|
Metric
|
DYN
|
|---|---|
Quick Ratio | 18.97 |
Current Ratio | 19.92 |
Interest Coverage | −45.49 |
Quick Ratio
DYN
Profitability
|
Metric
|
DYN
|
|---|---|
Return on Assets (Normalized) | −44.26% |
Return on Equity (Normalized) | −53.83% |
Return on Invested Capital (Normalized) | −48.83% |
Return on Assets
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Xbfzztp | Jfkljg | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fgbthkry | Kxjwhsz | $64B | |||
| argenx SE ADR
ARGX
| Zfxlrclsm | Hbdw | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dvpfgyh | Zrcds | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Srbvynqxhb | Cygnwv | $24B | |||
| BioNTech SE ADR
BNTX
| Czsllzbcd | Fgdnn | $22B | |||
| Incyte Corp
INCY
| Yxpmbwtqb | Grs | $20B | |||
| Moderna Inc
MRNA
| Cpdpjbrr | Mgkr | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wtcdsdrsd | Whd | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Mpvrmmx | Tkwn | $13B |
United States